NeonMind Biosciences Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NMDBF research report →
Companywww.neonmindbiosciences.com
NeonMind Biosciences Inc. engages in the discovery, development, and commercialization of medicinal and psychedelic mushrooms for mental illnesses. It is developing psilocybin-based products comprising mushroom-infused products and other mushroom-infused products to treat weight loss and management.
- CEO
- Penny Olga White BA, LLB
- IPO
- 2021
- HQ
- Oakville, ON, CA
Price Chart
Valuation
- Market Cap
- $8.54K
- P/E
- 0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.00
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 366.65%
- ROIC
- 315.46%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-2,034,000 · 71.78%
- EPS
- $-53.93 · -635.74%
- Op Income
- $-1,751,000
- FCF YoY
- 81.44%
Performance & Tape
- 52W High
- $0.23
- 52W Low
- $0.00
- 50D MA
- $0.23
- 200D MA
- $0.10
- Beta
- -0.88
- Avg Volume
- 0
Get TickerSpark's AI analysis on NMDBF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our NMDBF Coverage
We haven't published any research on NMDBF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NMDBF Report →